- Home
- AGPU vs ATOS Comparison
AGPU vs ATOS Comparison
Compare AGPU & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGPU | ATOS |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 36.2M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | AGPU | ATOS |
|---|---|---|
| Price | $5.59 | $5.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 3.8M | 49.8K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | $12,476.23 | N/A |
| Revenue Next Year | $55.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.53 |
| 52 Week High | $10.86 | $7.56 |
Technical Indicators
Market Signals| Indicator | AGPU | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 49.52 |
| Support Level | $1.46 | $0.66 |
| Resistance Level | $6.46 | $5.56 |
| Average True Range (ATR) | 0.89 | 0.33 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 32.21 | 14.13 |
Price Performance
Historical ComparisonAbout AGPU Axe Compute Inc. Common Stock
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.